Muhammad Sethi
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1275762130
Payments from drug & device makers
Across 973 payments — averaging $688.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$233K
- Amgen$179K
- Lilly USA, LLC$134K
- Shire North American Group Inc$68K
- Boehringer Ingelheim$22K
- Amarin Pharma, Inc.$22K
- plus $12K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 245 | $232,766 |
| Amgen(2 entities) | 222 | $178,530 |
| Lilly USA, LLC | 234 | $133,991 |
| Shire North American Group Inc | 116 | $67,574 |
| Boehringer Ingelheim | 26 | $22,380 |
| Amarin Pharma, Inc. | 36 | $22,181 |
| Johnson & Johnson | 10 | $7,886 |
| Sanofi-aventis U.S. LLC | 30 | $3,567 |
| Sequel Med Tech, LLC | 2 | $184 |
| Dexcom, Inc. | 11 | $155 |
| AbbVie | 8 | $126 |
| Mannkind Corporation | 7 | $96 |
| Abbott | 3 | $70 |
| Nestle Healthcare Nutrition Inc. | 2 | $47 |
| Medtronic | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Novartis | 2 | $36 |
| Antares Pharma, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Merck | 2 | $24 |
| Radius Health, Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $2 |
How this compares
$669,855 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Tucson
- Karen HerbstTucson$200K
- Stephen ThomsonTucson$135K
- Nora BarsonyTucson$121K
- Juan GalvezTucson$30K
- Maria PosadasTucson$24K
- Dorota PucykTucson$15K
- Alexander ZwartTucson$13K
- Neda EbrahimiTucson$11K
- Craig StumpTucson$10K
- Casey RendonTucson$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.